A pharmacist check of patients’ infection-related condition prior to drug preparation reduces anticancer drug wastage after mixing: a retrospective study

References

• Prasad V, De Jesús K, Mailankody SThe high price of anticancer drugs: origins, implications, barriers, solutionsNat Rev Clin Oncol201714381390 https://doi.org/10.1038/nrclinonc.2017.31
   PubMed Web of Science ®Google Scholar
• Shibata S, Matsushita M, Saito Y, Suzuki TAnticancer drug prescription patterns in Japan: future directions in cancer therapyTher Innov Regul Sci201852718723 https://doi.org/10.1177/2168479017751404
   PubMed Web of Science ®Google Scholar
• Lien K, Cheung MC, Chan KKAdjusting for drug wastage in economicJ Oncol Pract201612e369e379 https://doi.org/10.1200/JOP.2015.005876
   PubMed Web of Science ®Google Scholar
• Desoize G, Robert JIndividual dose adaptation of anticancer drugsEur J Cancer199430A6844885 1:STN:280:DyaK2M%2FgtV2lsw%3D%3D https://doi.org/10.1016/0959-8049(94)90304-2
   PubMed Web of Science ®Google Scholar
• Matsuo K, Nomura H, Uchiyama M, Miyazaki M, Imakyure OEstimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospitalBMC Health Serv Res20202011017 https://doi.org/10.1186/s12913-020-05822-1
   PubMed Web of Science ®Google Scholar
• Suzuki S, Gilbar P, Yu B, Matsuyama C, Yamaguchi MCurrent status of drug vial optimization use to prevent waste associated with injectable anticancer agentsJ Oncol Pharm Pract2019251244246 https://doi.org/10.1177/1078155218758501
   PubMed Web of Science ®Google Scholar
• Dooley MJ, Singh S, Michael MImplications of dose rounding of chemotherapy to the nearest vial sizeSupport Care Cancer200412653656
   PubMed Web of Science ®Google Scholar
• Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LBOverspending driven by oversized single dose vials of cancer drugsBMJ2016352 https://doi.org/10.1136/bmj.i788
   PubMedGoogle Scholar
• Patel S, Le ARounding rituximab dose to nearest vial sizeJ Oncol Pharm Pract2013193218222 1:CAS:528:DC%2BC2cXhs1OisLzE https://doi.org/10.1177/1078155212462439
   PubMedGoogle Scholar
• Francis SM, Heyliger A, Miyares MA, Viera MPotential cost savings associated with dose rounding antineoplastic monoclonal agentsJ Oncol Pharm Pract2015214280284 https://doi.org/10.1177/1078155214533369
   PubMed Web of Science ®Google Scholar
• Yamada H, Kobayashi R, Shimizu S, Yamada Y, Ishida M, Shimoda H, Kato-Hayashi H, Fujii H, Iihara H, Tanaka H, Suzuki AImplementation of a standardised pharmacist check of medical orders prior to preparation of anticancer drugs to reduce drug wastageInt J Clin Pract2020744 1:CAS:528:DC%2BB3cXltV2gu7w%3D https://doi.org/10.1111/ijcp.13464
   PubMed Web of Science ®Google Scholar
• Rolston KVInfections in cancer patients with solid tumors: a reviewInfect Dis Ther2018666983
   Google Scholar
• Taha A, Vinograd I, Sakhnini A, Eliakim-Raz N, Farbman L, Baslo R, Stemmer SM, Gafter-Gvili A, Leibovici L, Paul MThe association between infections and chemotherapy interruptions among cancer patients: prospective cohort studyJ Infect2015703223229 https://doi.org/10.1016/j.jinf.2014.10.008
   PubMed Web of Science ®Google Scholar
• Ang ZY, Cheah KY, Abdullah NB, Samsuri SB, Lee SH, Yem AW, Sriraman MAParenteral cytotoxic drug wastage at a tertiary hospital in Kuala Lumpur: how much and why?J Oncol Pharm Pract202026613061317 https://doi.org/10.1177/1078155219891209
   PubMed Web of Science ®Google Scholar
• Shih Y-CT, Xu Y, Liu L, Smieliauskas FRising prices of targeted oral anticancer medications and associated financial burden on medicare beneficiariesJ Clin Oncol20173524822489 https://doi.org/10.1200/JCO.2017.72.3742
   PubMed Web of Science ®Google Scholar
• Shayne M, Culakova E, Poniewierski MS, Dale DC, Crawford J, Wogu AF, Lyman GHRisk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignanciesJ Geriatr Oncol201344310318 https://doi.org/10.1016/j.jgo.2013.05.005
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 15 Sept 2021.
   Google Scholar
• Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt JESMO Guidelines CommitteeManagement of febrile neutropaenia: ESMO clinical practice guidelinesAnn Oncol201627Suppl 5v111v118 1:STN:280:DC%2BC2srgs1Kqsg%3D%3D https://doi.org/10.1093/annonc/mdw325
   PubMed Web of Science ®Google Scholar
• Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki HClinical effectiveness of neuraminidase inhibitors–oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in JapanJ Infect Chemother2012186858864 1:CAS:528:DC%2BC38XhvFSns7%2FM https://doi.org/10.1007/s10156-012-0428-1
   PubMed Web of Science ®Google Scholar
• Ryuko H, Otsuka FA comprehensive analysis of 174 febrile patients admitted to Okayama University HospitalActa Med Okayama2013674227237
   PubMed Web of Science ®Google Scholar
• Sproston NR, Ashworth JJRole of C-reactive protein at sites of inflammation and infectionFront Immunol20189754 https://doi.org/10.3389/fimmu.2018.00754
   PubMed Web of Science ®Google Scholar
• Yusa T, Tateda K, Ohara A, Miyazaki SNew possible biomarkers for diagnosis of infections and diagnostic distinction between bacterial and viral infections in childrenJ Infect Chemother201723296100 1:CAS:528:DC%2BC2sXls1yks7c%3D https://doi.org/10.1016/j.jiac.2016.11.002
   PubMed Web of Science ®Google Scholar
• Hart PC, Rajab IM, Alebraheem M, Potempa LAC-reactive protein and cancer-diagnostic and therapeutic insightsFront Immunol202011 1:CAS:528:DC%2BB3MXitVCgtLw%3D https://doi.org/10.3389/fimmu.2020.595835
   Web of Science ®Google Scholar
• Mahmoud FA, Rivera NIThe role of C-reactive protein as a prognostic indicator in advanced cancerCurr Oncol Rep20204250255 https://doi.org/10.1007/s11912-002-0023-1
   Google Scholar
• Stikbakke E, Richardsen E, Knutsen T, Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS, Thune IInflammatory serum markers and risk and severity of prostate cancer: the PROCA-life studyInt J Cancer202014718492 1:CAS:528:DC%2BC1MXitFOqtrfK https://doi.org/10.1002/ijc.32718
   PubMed Web of Science ®Google Scholar